LBA-4 Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Document Details

Document Type
Pub Defense Publication
Publication Date
Jul 01, 2021
Source ID
10.1016/j.annonc.2021.06.011

Entities

People

  • A. Kawazoe
  • Chung-You Shih
  • E. Van Cutsem
  • Haejun Chung
  • J. Tabernero
  • K. Shitara
  • L. Wyrwicz
  • Lin Shen
  • Liying Li
  • O. Barajas
  • O. Kolesnik
  • P. Bhagia
  • P. Weber
  • S. Lonardi
  • S. Luo
  • S. Qin
  • Y. Janjigian
  • Yan Tang
  • Yuanli Bai

Organizations

  • AbbVie
  • Astellas Pharma (United States)
  • AstraZeneca
  • Basilea Pharmaceutica
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • Eli Lilly and Company
  • GSK
  • National Cancer Institute
  • Novartis
  • Pfizer
  • United States Department of Defense